Pharmaceuticals, Biotechnology & Life Sciences

How a possible AstraZeneca‑BMS merger could reshape market access, innovation, and share pricing – dive into the numbers, risks, and upside of this £400 bn pharma deal.

AbbVie Q2 2026 review: revenue up 5.7 %, earnings grow 18%, R&D stays lean, and analysts upgrade targets while patent expirations and biosimilar risk loom.

Explore Bayer AG’s Q2 2026 earnings: how the company stacks against European peers, macro trends, and what the 14:00 GMT call means for investors.

Merck KGaA’s next quarterly report: see how AI, energy‑efficiency upgrades and geopolitical risk shape its earnings and future growth amid DAX’s record‑high momentum.

Explore how Pfizer’s Q2 2026 earnings reveal the impact of patent expirations, COVID‑19 sales decline, and its new oncology/obesity pipeline.

Novo Nordisk’s shares fell after the Phase‑3 ZEUS study showed Ziltivekimab lowered inflammatory biomarkers but missed cardiovascular benefit, impacting future approvals and market outlook.

J&J’s new Ottava robot, cleared by the FDA, could reshape minimally invasive surgery with AI‑driven precision, lower costs, and high‑value reimbursement, promising robust investor upside.

Danaher’s leadership transition: Julie Sawyer Montgomery becomes CEO with a $20 million equity award, while outgoing CEO Rainer Blair stays on board as senior advisor.

Gilead Sciences Q4 earnings on Aug 4, 2026: see how safety, efficacy data and regulatory updates could shift biopharma valuations and market momentum.

Haleon PLC boosts India presence: ₹2,000 cr local plant, low‑price oral‑health packs, and a 12% revenue lift, aiming to capture 15% market share.